Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study

Abstract Background We sought to determine whether prenatal supplementation with the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) would increase markers of insulin sensitivity in maternal or cord blood compared with placebo supplementation. A secondary aim was to eva...

Full description

Bibliographic Details
Main Authors: Joey A. England, Joses Jain, Bradley D. Holbrook, Ronald Schrader, Clifford Qualls, Ellen Mozurkewich
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Pregnancy and Childbirth
Subjects:
EPA
DHA
Online Access:https://doi.org/10.1186/s12884-019-2599-6
id doaj-bee64c76caad41ec87ffc02c39212ec2
record_format Article
spelling doaj-bee64c76caad41ec87ffc02c39212ec22020-11-29T12:09:08ZengBMCBMC Pregnancy and Childbirth1471-23932019-11-011911810.1186/s12884-019-2599-6Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health studyJoey A. England0Joses Jain1Bradley D. Holbrook2Ronald Schrader3Clifford Qualls4Ellen Mozurkewich5Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School, University of Texas Health Science Center at HoustonDepartment of Obstetrics and Gynecology, University of New MexicoDepartment of Obstetrics and Gynecology, University of New MexicoClinical and Translational Center, University of New MexicoClinical and Translational Center, University of New MexicoDepartment of Obstetrics and Gynecology, University of New MexicoAbstract Background We sought to determine whether prenatal supplementation with the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) would increase markers of insulin sensitivity in maternal or cord blood compared with placebo supplementation. A secondary aim was to evaluate the association of serum EPA and DHA fractions with adiponectin, leptin and the adiponectin:leptin ratio (ALR). We hypothesized that omega-3 fatty acid supplementation would increase markers of insulin sensitivity in maternal and umbilical cord plasma. Methods We analyzed stored plasma samples collected from a prior 3-arm prospective, double-blinded, randomized controlled trial in which 126 women with singleton pregnancies between 12- and 20-weeks’ gestation were randomized to receive: 1) an EPA-rich fish oil supplement, 2) a DHA-rich fish oil supplement, or 3) a soy oil placebo. Maternal venous blood samples were collected at 12–20 weeks gestation (before supplementation) and at 34–36 weeks gestation. At delivery, cord blood was collected. Samples were analyzed using sandwich enzyme-linked immunosorbent assay kits to quantify leptin and adiponectin levels which were utilized to calculate the ALR, a proxy measure for insulin sensitivity. Results We found no difference in adiponectin, leptin, and the ALR between the treatment and placebo groups at baseline, after supplementation, or in umbilical cord blood. In regression analyses, higher maternal serum DHA fraction was associated with increased ALR before (p = 0.01) and after (p = 0.04) DHA supplementation. There was no association of EPA fraction with any measure of insulin sensitivity. Cord blood DHA fraction was significantly associated with cord plasma leptin (p = 0.02). Early pregnancy BMI was significantly associated with maternal leptin levels at baseline and in late pregnancy (p < 0.001) and was inversely associated with the ALR (p < 0.001). The ALR decreased significantly between the early and late pregnancy visits (p < 0.001). Pregnancy weight gain was inversely associated with the ALR (P. < 0.02). Conclusions EPA- and DHA- rich fish oil supplementation had no effect on plasma markers of insulin sensitivity. However, maternal serum DHA fraction was significantly associated with markers of insulin sensitivity. Trial registration https://clinicaltrials.gov/, registration number NCT00711971, 7/7/2008.https://doi.org/10.1186/s12884-019-2599-6EPADHAInsulin sensitivityOmega-3 fatty acids
collection DOAJ
language English
format Article
sources DOAJ
author Joey A. England
Joses Jain
Bradley D. Holbrook
Ronald Schrader
Clifford Qualls
Ellen Mozurkewich
spellingShingle Joey A. England
Joses Jain
Bradley D. Holbrook
Ronald Schrader
Clifford Qualls
Ellen Mozurkewich
Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
BMC Pregnancy and Childbirth
EPA
DHA
Insulin sensitivity
Omega-3 fatty acids
author_facet Joey A. England
Joses Jain
Bradley D. Holbrook
Ronald Schrader
Clifford Qualls
Ellen Mozurkewich
author_sort Joey A. England
title Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
title_short Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
title_full Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
title_fullStr Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
title_full_unstemmed Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
title_sort effect of prenatal epa and dha on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study
publisher BMC
series BMC Pregnancy and Childbirth
issn 1471-2393
publishDate 2019-11-01
description Abstract Background We sought to determine whether prenatal supplementation with the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) would increase markers of insulin sensitivity in maternal or cord blood compared with placebo supplementation. A secondary aim was to evaluate the association of serum EPA and DHA fractions with adiponectin, leptin and the adiponectin:leptin ratio (ALR). We hypothesized that omega-3 fatty acid supplementation would increase markers of insulin sensitivity in maternal and umbilical cord plasma. Methods We analyzed stored plasma samples collected from a prior 3-arm prospective, double-blinded, randomized controlled trial in which 126 women with singleton pregnancies between 12- and 20-weeks’ gestation were randomized to receive: 1) an EPA-rich fish oil supplement, 2) a DHA-rich fish oil supplement, or 3) a soy oil placebo. Maternal venous blood samples were collected at 12–20 weeks gestation (before supplementation) and at 34–36 weeks gestation. At delivery, cord blood was collected. Samples were analyzed using sandwich enzyme-linked immunosorbent assay kits to quantify leptin and adiponectin levels which were utilized to calculate the ALR, a proxy measure for insulin sensitivity. Results We found no difference in adiponectin, leptin, and the ALR between the treatment and placebo groups at baseline, after supplementation, or in umbilical cord blood. In regression analyses, higher maternal serum DHA fraction was associated with increased ALR before (p = 0.01) and after (p = 0.04) DHA supplementation. There was no association of EPA fraction with any measure of insulin sensitivity. Cord blood DHA fraction was significantly associated with cord plasma leptin (p = 0.02). Early pregnancy BMI was significantly associated with maternal leptin levels at baseline and in late pregnancy (p < 0.001) and was inversely associated with the ALR (p < 0.001). The ALR decreased significantly between the early and late pregnancy visits (p < 0.001). Pregnancy weight gain was inversely associated with the ALR (P. < 0.02). Conclusions EPA- and DHA- rich fish oil supplementation had no effect on plasma markers of insulin sensitivity. However, maternal serum DHA fraction was significantly associated with markers of insulin sensitivity. Trial registration https://clinicaltrials.gov/, registration number NCT00711971, 7/7/2008.
topic EPA
DHA
Insulin sensitivity
Omega-3 fatty acids
url https://doi.org/10.1186/s12884-019-2599-6
work_keys_str_mv AT joeyaengland effectofprenatalepaanddhaonmaternalandcordbloodinsulinsensitivityasecondaryanalysisofthemothersomega3andmentalhealthstudy
AT josesjain effectofprenatalepaanddhaonmaternalandcordbloodinsulinsensitivityasecondaryanalysisofthemothersomega3andmentalhealthstudy
AT bradleydholbrook effectofprenatalepaanddhaonmaternalandcordbloodinsulinsensitivityasecondaryanalysisofthemothersomega3andmentalhealthstudy
AT ronaldschrader effectofprenatalepaanddhaonmaternalandcordbloodinsulinsensitivityasecondaryanalysisofthemothersomega3andmentalhealthstudy
AT cliffordqualls effectofprenatalepaanddhaonmaternalandcordbloodinsulinsensitivityasecondaryanalysisofthemothersomega3andmentalhealthstudy
AT ellenmozurkewich effectofprenatalepaanddhaonmaternalandcordbloodinsulinsensitivityasecondaryanalysisofthemothersomega3andmentalhealthstudy
_version_ 1724412165546311680